Worldwide Urothelial Cancer Drugs Market Size, Share & Trends Analysis Report (2018-2023) by Treatment Class (Chemotherapy, Immunotherapy)

DUBLIN, Oct. 31, 2018 /PRNewswire/ --

The "Urothelial Cancer Drugs Market Size, Share & Trends Analysis Report By Treatment Class (Chemotherapy, Immunotherapy), By Major Markets, Competitive Landscape, And Segment Forecasts, 2018 - 2023" report has been added to ResearchAndMarkets.com's offering.

The global urothelial cancer drugs market size is expected to reach USD 3.6 billion by 2023., exhibiting a 22.9% CAGR during the forecast period. Availability of novel drugs, presence of a strong pipeline, rising disease incidence, unhealthy lifestyle, and increasing awareness are driving this market.

Urothelial cancer is the ninth most common malignancy in the world, with approximately 2.5 million patients and 420,000 newly diagnosed cases each year. Approximately 59% of bladder cancer cases occur in developed regions such as North America and Europe. The disease has the highest lifetime cost of care per patient among all tumors in U.S. due to its high relapse rate and invasive lifelong monitoring including cystoscopy follow-ups.

Bladder transitional cell carcinoma (TCC) is the most common histology, accounting for nearly 90% of all urinary cancer cases. Urothelial cancer is clinically divided into three categories: non-muscle invasive bladder cancer (NMIBC, early stage), muscle invasive disease (MIBC, mid stage), and metastatic disease (late stage). At diagnosis, approximately 70% of cases are non-muscle invasive disease, 20% are at the muscle invasive stage, and 10% are at the advanced stage.

Key Findings

• The U.S. dominated the urothelial cancer market, with more than 60% of the market in 2017. Several factors such as presence of a large target population, increased adoption of novel therapeutics, and multiple product launches will drive the market in this region.
• The therapeutic landscape is expected to witness a paradigm shift toward combination therapies and novel immuno-oncology products. Combination regimens, particularly checkpoint inhibitors, are likely to be introduced in the first-line setting. Immune checkpoint blockade therapy is expected to replace the current standard of care in bladder cancer in the foreseeable future.
• Therapeutic development in second-line setting for chemotherapy-intolerant patients is expected to have a major impact in the urothelial cancer space.
• Urothelial cancer presents a strong opportunity for introducing first-in-class treatments due to high unmet needs. Opportunities remain in the non-muscle invasive bladder cancer (NMIBC) setting where there exists an unmet need for treatment options for patients who are BCG-intolerant or ineligible.

Topics Covered

Chapter 1 Research Methodology
1.1. Information Procurement
1.2. Information or Data Analysis
1.2.1 Market Formulation & Validation

Chapter 2 Executive Summary

Chapter 3 Disease Primer and Epidemiology
3.1. Disease Primer
3.2. Epidemiology

Chapter 4 Global Urothelial Cancer Drugs Market Overview
4.1 Market by Treatment Class
4.2 Market Size and Forecast 2017- 2023
4.3 Market Share Distribution, by Company 2017- 2023
4.4 Market Dynamics and Brand Strategies
4.5 Patent Expiry Analysis
4.6 Urothelial Cancer Market: Drivers and Restraints
4.6.1 Drivers
4.6.2 Challenges
4.7 M&A, Deal Landscape (2013-2018 YTD)
4.7.1 Mergers & Acquisitions
4.7.2 Deals Landscape
4.8 Emerging Markets
4.9 Reimbursement Scenario
4.10 Urothelial Cancer Sector SWOT

Chapter 5 Urothelial Cancer Drugs Market: Pipeline Intelligence
5.1. Pipeline Landscape
5.1.1 Leading Drugs in Development
5.1.2 Key R&D Trends
5.2 Pipeline Landscape
5.2.1 Late Stage Pipeline and Sales Forecast
5.2.2 Profiles of Disruptive Drugs
5.3 Global Pipeline Forecast

Chapter 6 Company Profiles
6.1 Merck
6.1.1 Company Overview
6.1.2 Current Product Portfolio
6.1.3 Product Forecast Sales Through 2023
6.1.4 Strategic Initiatives
6.1.4.1 Key Company News Flow
6.1.5 Pipeline Analysis & Overview
6.1.6 SWOT
6.2 Roche
6.3 Bristol-Myers Squibb
6.4 AstraZeneca
6.5 Pfizer

Chapter 7 Market Outlook
7.1 What the Future Holds
7.2 The Winners and Losers
7.2.1 Winners
7.2.2 Losers
7.3 Emerging Companies & Technology Platforms
7.4 The Road Ahead

For more information about this report visit https://www.researchandmarkets.com/research/7tl69s/worldwide?w=5

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

Related Links

http://www.researchandmarkets.com